



Aalborg Universitet

AALBORG UNIVERSITY  
DENMARK

## **Association between intravenous iron therapy and short-term mortality risk in older patients undergoing hip fracture surgery**

*an observational study*

Clemmensen, Silas Zacharias; Kragholm, Kristian H.; Melgaard, Dorte; Hansen, Lene T.; Riis, Johannes; Cavallius, Christian; Mørch, Marianne M.; Krogager, Maria Lukács

*Published in:*

Journal of Orthopaedic Surgery and Research

*DOI (link to publication from Publisher):*

[10.1186/s13018-021-02462-x](https://doi.org/10.1186/s13018-021-02462-x)

*Creative Commons License*

CC BY 4.0

*Publication date:*

2021

*Document Version*

Publisher's PDF, also known as Version of record

[Link to publication from Aalborg University](#)

*Citation for published version (APA):*

Clemmensen, S. Z., Kragholm, K. H., Melgaard, D., Hansen, L. T., Riis, J., Cavallius, C., Mørch, M. M., & Krogager, M. L. (2021). Association between intravenous iron therapy and short-term mortality risk in older patients undergoing hip fracture surgery: an observational study. *Journal of Orthopaedic Surgery and Research*, 16(1), [320]. <https://doi.org/10.1186/s13018-021-02462-x>

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- ? You may not further distribute the material or use it for any profit-making activity or commercial gain
- ? You may freely distribute the URL identifying the publication in the public portal ?

### **Take down policy**


If you believe that this document breaches copyright please contact us at [vbn@aub.aau.dk](mailto:vbn@aub.aau.dk) providing details, and we will remove access to the work immediately and investigate your claim.

RESEARCH ARTICLE

Open Access



# Association between intravenous iron therapy and short-term mortality risk in older patients undergoing hip fracture surgery: an observational study

Silas Zacharias Clemmensen<sup>1,2\*</sup> , Kristian H. Kragholm<sup>1,3,4</sup>, Dorte Melgaard<sup>1,5</sup>, Lene T. Hansen<sup>6</sup>, Johannes Riis<sup>1</sup>, Christian Cavallius<sup>2</sup>, Marianne M. Mørch<sup>6</sup> and Maria Lukács Krogager<sup>4,7</sup>

## Abstract

**Background:** Anemia is common among ortho-geriatric hip fracture patients and is associated with prolonged recovery and increased postoperative mortality rate. Intravenous iron seems to increase hemoglobin recovery and reduce the mortality rate in patients undergoing orthopedic surgeries. This study investigated the association between short-term mortality risk and intravenous iron therapy in older patients undergoing hip fracture surgery.

**Methods:** This observational study included 210 patients undergoing hip fracture surgery from July 2018 to May 2020. These 210 patients were alive and had a hemoglobin  $\leq 6.5$  mmol/L on the 3rd postoperative day. In May 2019, a local intravenous iron therapy protocol was implemented and recommended intravenous iron (Monofer©) if hemoglobin on the 3rd postoperative day was  $\leq 6.5$  mmol/L. According to the treatment of postoperative anemia between the 1st and 3rd day post-surgery, the patients were divided into four groups: no treatment ( $n=52$ ), blood transfusion ( $n=38$ ), IV Monofer ( $n=80$ ), and blood transfusion and IV Monofer ( $n=40$ ). Primary outcome was 30-day mortality post-surgery. The secondary outcome was the impact on hemoglobin level 14–30 days postoperatively. Multivariable Cox regression was used to estimate the 30-day mortality standardized for covariates.

**Results:** Of 210 patients, 17 (8.1%) died within 30 days after surgery. There was a significantly lower mortality among the patients who received IV Monofer compared to those who received no treatment (HR 0.17, 95% CI [0.03–0.93],  $P = 0.041$ ). Among the 86 patients with available hemoglobin measurements within 14 to 30 days post-surgery, there was no significant difference in hemoglobin level between the various treatment groups (mean 6.6 mmol/L,  $P = 0.1165$ ).

**Conclusion:** IV Monofer on the 3rd postoperative day in older hip fracture patients seemed to reduce 30-day mortality compared with no treatment. No significant differences in hemoglobin levels between 14 and 30 days post-surgery across treatment groups were found, although this was assessed in a subset of patients with available hemoglobin levels warranting further study.

**Keywords:** Hip fractures, Older people, Mortality, Anemia, Iron

\* Correspondence: [silas.clemmensen@rn.dk](mailto:silas.clemmensen@rn.dk)

<sup>1</sup>Center for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark

<sup>2</sup>Department of Orthopedic Surgery, Aalborg University Hospital, Hjørring, Denmark

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Background

Anemia is a severe complication among older people undergoing hip fracture surgery. Evidence suggests that anemia is associated with prolonged recovery, decreased mobility, and increased postoperative mortality rate [1–6]. Development of anemia is multifactorial: blood lost at the fracture site and during surgery, iatrogenic hemodilution, the presence of chronic diseases and inhibition of erythropoiesis, and functional iron deficiency due to trauma- and surgery-induced inflammation [7–9]. In the postoperative period, guidelines recommend treatment of severe anemia with allogeneous blood transfusion (ABT). Besides heavy expense, ABT causes a higher risk of postoperative bacterial infections because of an immunological suppression, thus extending the hospitalization [10–12]. The alternative to ABT is stimulation of erythropoiesis with erythropoietin (EPO) and iron which seems to be associated with improved patient outcomes, reduced blood product utilization, reduced mortality, and product-related cost savings [13–22].

Several studies investigated the efficacy of intravenous (IV) iron administration perioperatively in patients undergoing major surgeries. On one hand, studies suggested that IV iron preoperatively is associated with reduced ABT rate, fewer nosocomial infections, decreased mortality, higher postoperative hemoglobin-concentration, and shorter hospitalization [12, 17, 19–21, 23–26]. On the other hand, a recent review concluded that the evidence for administration of IV iron preoperatively is deficient [27]. As for postoperative IV iron administration, the results are also contradictory. Kim et al. investigated the implementation of a strict transfusion protocol and postoperative IV iron among patients undergoing orthopedic hip surgery. They found that postoperative IV iron was related to a significantly lower number of transfused blood units per patient and higher hemoglobin-concentration 6 weeks postoperatively [28]. Contrarily, Moppett et al. have found no benefit of three daily doses of IV iron on the hemoglobin recovery 7 days postoperatively among older patients undergoing hip fracture surgery [29, 30].

As such, the evidence for administration of IV iron among older patients undergoing major orthopedic surgeries is scarce and conflicting. Therefore, in older patients undergoing hip fracture surgery, we wanted to investigate the impact of postoperative IV iron therapy on 30-day mortality and hemoglobin level 14–30 days postoperatively.

## Methods

### Study design and setting

This observational, single-center study of IV iron therapy included older patients admitted with an acute hip fracture at the Department of Orthopedic Surgery,

Aalborg University Hospital, Hjørring, Denmark. In May 2019, a new local IV iron therapy protocol was implemented at the department and recommends IV iron isomaltoside 1000 (Monofer®) after surgery for hip fracture on the 3rd postoperative day if hemoglobin  $\leq 6.5$  mmol/L ( $\leq 10.4$  g/dL) day three postoperatively. Therefore, the study investigates the time before (from July 2018 to May 2019) and after (August 2019 to May 2020) the implementation of the protocol.

### Outcome and follow-up

The primary outcome of the study is to analyze the 30-day mortality after surgery. The secondary outcome is to evaluate the efficacy of IV Monofer on the hemoglobin within 14 to 30 days postoperatively, although no systematic long-term follow-up on the hemoglobin was part of the IV iron therapy protocol.

### Study population

Patients admitted with an acute hip fracture at the Department of Orthopedic Surgery, Aalborg University Hospital, Hjørring, Denmark, from July 2018 to May 2019 (study period 1) and from August 2019 to May 2020 (study period 2) were included. Thus, the study period 1 was before the implementation of the iron treatment protocol, and IV iron was therefore administered non-systematically. In study period 2, IV iron was administered systematically to all patients with a hemoglobin  $\leq 6.5$  mmol/L on the 3rd postoperative day. This eligibility criterion of the iron therapy protocol is based on the evidence from major colorectal surgeries among patients diagnosed with colorectal cancer [31, 32]. Therefore, all patients with a hemoglobin  $> 6.5$  mmol/L on the 3rd postoperative day were excluded. Furthermore, the patients who died in hospital before day three and the patients who were discharged immediately after surgery were excluded. Finally, the patients who fulfilled the eligibility criteria to IV iron but did not receive it because of patient denial, missing cooperation, or transfer to another hospital before day three was excluded.


### Study interventions

An international consensus states postoperative anemia as hemoglobin  $< 6.83$  mmol/L ( $< 11.0$  g/dL) [16]. In this study, a hemoglobin  $\leq 6.5$  mmol/L on the 3rd postoperative day was defined as eligible according to the iron therapy protocol [33]. However, due to the non-systematic administration of IV iron in study period 1, IV iron was in this first period only prescribed to some patients after medical assessment by a geriatrician. Furthermore, if the postoperative anemia was severe, the treatment was initiated the 1st day after the surgery. After the implementation of the iron therapy protocol,

IV iron was administered systematically. The patients with a hgb  $\leq 6.5$  mmol/L on the 3rd postoperative day were administered IV iron. The patients received a single dose of IV iron isomaltoside 1000 (Monofer®, Pharmacosmos) 20 mg/kg diluted in 100 mL isotone saline solution with an infusion time of 30 min while they were observed for adverse reactions [33, 34]. The indications for ABT followed the current local guidelines [35]. Therefore, the patients with a hemoglobin  $\leq 6.5$  mmol/L on the 3rd postoperative day were divided according to which treatment of postoperative anemia they received between day one and day three postoperatively. Accordingly, whether they received no treatment, IV iron, ABT, or both IV iron and ABT, see Fig. 1.

#### Data collection

The data collection was performed in two steps and was obtained from the patients' medical records retrospectively. Information was obtained on hospital admission date, hospital discharge date, number of readmissions, type of hip fracture, body mass index (BMI), 30 days mortality postoperatively, hgb at day one preoperatively, at day one and day three and between day 14 and 30 postoperatively, number of ABT, administration of IV Monofer, and concomitant comorbidities. The type of hip fracture was coded according to the World Health Organization International Classification of Disease (ICD), and the type of orthopedic procedure was classified according to Nomenclature for Properties and Units (NPU-codes). Secondly, we registered whether the patients were admitted from and discharged to home or



nursing home and if they were readmitted to the hospital. Finally, we registered, date of surgery, reoperation during hospitalization, when IV Monofer, ABT, and antibiotics were administered, type of anesthesia and operation and perioperative blood loss.

#### Comorbidities and concomitant medication

At hospitalization, we identified confounding factors such as comorbidities and concomitant medication. We consulted the national Shared Medication Record for information about the patients' medication at submission time. Furthermore, we identified the occurrence of polypharmacy. Polypharmacy was defined as five or more medications according to a systematic review which found this to be the most commonly reported definition of polypharmacy [36].

Clinically relevant comorbidities were obtained from the patients' medical records, classified according to the Charlson's Comorbidity Index (CCI), and include previous myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, mild to severe liver disease, diabetes mellitus with or without complications, hemiplegia, moderate to severe chronic kidney disease, localized or metastatic solid tumor, leukemia, lymphoma, and AIDS [37, 38].

#### Statistical analysis

Categorical variables were presented as counts and percentages, and continuous variables as median and 25th and 75th percentiles. The  $\chi^2$  test was used to evaluate differences for categorical variables, and the Kruskal-Wallis test to evaluate differences for non-normally distributed continuous variables. Kaplan-Meier cumulative mortality curves were plotted for the four treatments of postoperative anemia to illustrate the crude 30-day mortality incidence. Using multivariable Cox regression and average treatment effect analysis (ATE), we reported the 30-day absolute and relative mortality risk standardized for the age, sex, medication, and comorbidity distribution of all patients eligible for analysis. A two-sided  $p$  value was considered statistically significant below 0.05. All data management and analyses were performed using and R, version 3.5.0 [39].

## Results

### Patients

In total, 400 patients were recruited in the two study periods. After excluding patients not fulfilling the inclusion criteria, a total of 210 patients with hemoglobin  $\leq 6.5$  mmol/L on the 3rd postoperative day were included. We identified 52 patients with no treatment, 38 receiving

ABT, 80 receiving IV Monofer, and 40 receiving IV Monofer and ABT.

### Characteristics

The characteristics of the study population reported are presented in Table 1. The population consisted of 107 (51%) females and 103 (49%) males, and the average age was 83.5 ( $\pm 8.7$ ) years. There was no significant difference among the treatment groups regarding gender, age, BMI, CCI, admission source, and length of stay. However, patients in ABT and in the IV Monofer and ABT group had significantly more polypharmacy than patients in the other treatment groups. Furthermore, the patients receiving no treatment had significantly lower perioperative blood loss ( $185.7 \pm 108.9$  mL), fewer extracapsular fractures (44.2%), and fewer fixations with intramedullary nails (55.2%) than the other patients. Additionally, there was a significant difference in hemoglobin preoperatively and postoperatively among the treatment groups. The highest preoperative hemoglobin is 7.9 ( $\pm 0.7$ ) mmol/L in the IV Monofer group, and the lowest is 6.8 ( $\pm 1$ ) mmol/L in the IV Monofer and ABT group. The boxplot in Fig. 2 shows the distribution of the hemoglobin postoperative day three by the three possible treatment groups plus no treatment. Finally, a notable result was the significant change in choice of treatment in the two study periods,  $p < 0.0001$ . In study period 2,  $N=103$ , 101 patients (98%) received IV Monofer, 34 patients (33%) received ABT, and only 1 (1%) received no treatment. Contrarily, in study period 1,  $N=107$ , 19 patients (17.8%) received IV Monofer, 42 patients (39.3%) received ABT, and 51 patients (47.6%) received no treatment.

### Mortality within 30 days after surgery

In the population of 210 patients with hemoglobin  $\leq 6.5$  mmol/L on the 3rd postoperative day, 17 died during 30-day follow-up (8.1%). The main causes of death were age-related physical debility (52.9%) and a severe postoperative infection causing septic shock (23.5%). All other causes of death are reported in Additional file 1 Table S1. When stratified after treatment of postoperative anemia, the mortality was 9.6 (no treatment), 10.5 (ABT), 3.8 (IV Monofer), and 12.5% (IV Monofer and ABT), respectively. The survival curves are illustrated in Fig. 3. The results of the average treatment effect analysis and multivariable Cox regression model of the 210 patients stratified by treatment of postoperative anemia are shown in Table 2. The lowest mortality was observed in the IV Monofer treatment group (HR 0.41, 95% CI [0.089–1.887],  $P = 0.254$ ). The average treatment effect analysis shows that the lowest standardized absolute mortality risk was observed in the two groups that received IV Monofer. Thus, the average risk in the IV

**Table 1** Demographics among patients with hemoglobin  $\leq 6.5$  mmol/L on the 3rd postoperative day

	No treatment (n=52)	ABT (n=38)	IV Monofer (n=80)	IV Monofer and ABT (n=40)	Total (n=210)	p value
<b>Gender</b>						
Female	28 (53.8)	20 (52.6)	41 (51.2)	18 (45.0)	107 (51.0)	
Male	24 (46.2)	18 (47.4)	39 (48.8)	22 (55.0)	103 (49.0)	0.853
<b>Age</b>	82.6 (9.1)	83.2 (7.1)	83.6 (8.9)	84.7 (9.2)	83.5 (8.7)	0.709
<b>BMI (kg/m<sup>2</sup>)</b>	24.1 (4.2)	24 (5.1)	24.2 (3.9)	23.2 (3.8)	23.9 (4.2)	0.655
<b>Charlson Comorbidity Index</b>	1.9 (2)	2.7 (2.1)	1.9 (2.2)	2.1 (1.7)	2.1 (2.1)	0.219
<b>Polypharmacy (<math>\geq 5</math> medications)</b>	34 (65.4)	33 (86.8)	55 (68.8)	34 (85.0)	156 (74.3)	0.023*
<b>Admission source</b>						
Home-independent	38 (73.1)	27 (71.1)	55 (68.8)	29 (72.5)	149 (71.0)	
Nursing home	14 (26.9)	11 (28.9)	25 (31.2)	11 (27.5)	61 (29.0)	0.951
<b>Study period</b>						
1	51 (98.1)	37 (97.4)	12 (15.0)	7 (17.5)	107 (51.0)	
2	1 (1.9)	1 (2.6)	68 (85.0)	33 (82.5)	103 (49.0)	< 0.001*
<b>Fracture</b>						
Intracapsular	29 (55.8)	14 (36.8)	31 (38.8)	13 (32.5)	87 (41.4)	
Extracapsular	23 (44.2)	24 (63.2)	49 (61.2)	27 (67.5)	123 (58.6)	0.098
<b>Operation</b>						
Arthroplasty	19 (36.5)	16 (42.1)	23 (28.8)	7 (17.5)	65 (31.0)	
Intramedullary nails	19 (36.5)	21 (55.3)	48 (60.0)	30 (75.0)	118 (56.2)	
AO screws	2 (3.8)	0 (0.0)	3 (3.8)	1 (2.5)	6 (2.9)	
Dynamic hip screws	7 (13.5)	1 (2.6)	4 (5.0)	1 (2.5)	13 (6.2)	
Other	5 (9.6)	0 (0.0)	2 (2.5)	1 (2.5)	8 (3.8)	0.014*
<b>Time to theatre (days)</b>	0.6 (0.5)	0.8 (0.8)	0.8 (0.5)	0.7 (0.6)	0.7 (0.6)	0.425
<b>Preoperative Hgb (mmol/L)</b>	7.7 (0.8)	7.4 (1)	7.9 (0.7)	6.8 (1)	7.5 (0.9)	< 0.001*
Missing	9	5	19	10	43	
<b>Perioperative blood loss (mL)</b>	185.7 (108.9)	387.1 (414.1)	205.1 (159.9)	254.7 (196.1)	246.8 (241.1)	0.001*
Missing	17	7	21	8	53	
<b>Hgb postoperative day 1 (mmol/L)</b>	6.3 (0.6)	5.4 (0.8)	6.1 (0.6)	5.1 (0.6)	5.8 (0.8)	< 0.001*
Missing	2	0	0	0	2	
<b>Hgb postoperative day 3 (mmol/L)</b>	5.8 (0.5)	5.4 (0.7)	5.6 (0.5)	5.2 (0.7)	5.6 (0.6)	< 0.001*
<b>Hgb postoperative between day 14–30 (mmol/L)</b>	6.3 (0.7)	6.4 (0.5)	6.8 (0.6)	6.6 (0.8)	6.6 (0.7)	0.116
Missing because deceased	5	4	2	4	15	
Missing because no hgb control	28	21	48	12	109	
<b>Length of stay (days)</b>	6.5 (3.9)	7.1 (4)	5.9 (2.1)	6.9 (2.6)	6.5 (3.1)	0.177
<b>Discharged to</b>						
Home-independent	18 (34.6)	14 (36.8)	37 (46.2)	14 (35.0)	83 (39.5)	
Nursing home	34 (65.4)	20 (52.6)	43 (53.8)	24 (60.0)	121 (57.6)	
Dead in hospital	0 (0.0)	4 (10.5)	0 (0.0)	2 (5.0)	6 (2.9)	0.023*

**Table 1** Demographics among patients with hemoglobin ≤ 6.5 mmol/L on the 3rd postoperative day (Continued)

	No treatment (n=52)	ABT (n=38)	IV Monofer (n=80)	IV Monofer and ABT (n=40)	Total (n=210)	p value
<b>Readmission/transmission to ICU<sup>a</sup></b>						
Readmitted	13 (25.0)	5 (13.2)	14 (17.5)	10 (25.0)	42 (20.0)	
Transmitted to ICU <sup>a</sup>	0 (0.0)	0 (0.0)	1 (1.2)	1 (2.5)	2 (1.0)	0.558

Data are presented as mean ± SD (age, BMI, Charlson Comorbidity Index, perioperative blood loss, time to theatre, hemoglobin levels, length of stay) or number of patients and percentage (all others)

<sup>a</sup>Intensive Care unit


\*p < 0.05

Monofer and IV Monofer and ABT group was 2.31 and 9.5%, respectively. Additionally, the highest average mortality risk was observed in the no treatment and ABT group, with 18.49% and 17.77%, respectively. Hence, the IV Monofer group had an average mortality risk of 16.31% lower than the no treatment group and 15.46% lower than the ABT group.

The results of the average treatment effect analysis and multivariable Cox regression when comparing the no treatment group with the IV Monofer group and the ABT group with the IV Monofer and ABT group, respectively, are presented in Tables 3 and 4. Administration of IV Monofer was associated with significantly decreased mortality risk compared to no treatment (HR 0.17, 95% CI [0.03–0.93], P = 0.041). However, the combination of IV Monofer and ABT showed a trend towards increased mortality compared to ABT alone (HR 1.34, 95% CI [0.269–6.653], P = 0.7215).


**Hemoglobin levels 14–30 days after surgery**

When assessing the average hemoglobin postoperatively between day 14 and 30, a total of 124 (59%) patients was missing a hemoglobin level. Of the 124 patients missing hemoglobin level between 14 to 30 days after surgery, 15 (12%) were missing because they died before a new hemoglobin level was measured. The characteristics of these patients are reported in Additional file 1 Table S1. Furthermore, 109 (88%) patients had missing hemoglobin because it was not controlled at a general practitioner or at the geriatric outpatient clinic. Therefore, of the 210 patients, only 41% of them had their hemoglobin level controlled. Nevertheless, the patients treated with IV Monofer had the highest hemoglobin levels 14–30 days after surgery (6.8 ± 0.6 mmol/L) and the patients without treatment had the lowest (6.3 ± 0.7 mmol/L). Yet, no significant results between the four treatment groups were found.



<sup>1</sup>No treatment, <sup>2</sup>IV Monofer, <sup>3</sup>ABT, <sup>4</sup>IV Monofer & ABT

**Fig. 2** Hemoglobin level (mmol/L) on the 3rd postoperative day stratified by treatment groups. <sup>1</sup>No treatment, <sup>2</sup>IV Monofer, <sup>3</sup>ABT, <sup>4</sup>IV Monofer and ABT



Survival curves among the patients with hgb ≤ 6.5 mmol/L on the 3rd postoperative day stratified by treatment of postoperative anemia N=210.

**Fig. 3** Kaplan-Meier curves. Survival curves among the patients with hgb ≤ 6.5 mmol/L on the 3rd postoperative day stratified by treatment of postoperative anemia N=210

**Discussion**

This study analyzed the impact of a new IV iron therapy protocol among older patients with hip fracture and postoperative anemia according to 30-day mortality and hemoglobin levels 14–30 days postoperatively. The major finding was that the patients with hemoglobin ≤ 6.5 mmol/L on the 3rd postoperative day who only received IV Monofer had a significantly decreased risk of 30-day mortality compared to the patients with no treatment. The patients in the IV Monofer and the no treatment group had no significant difference in their comorbidity and pre- or postoperative hemoglobin level that could explain the decreased short-term mortality in the IV Monofer group. A plausible reason to the decreased short-term mortality is that 98.1% of the patients in the no treatment group was hospitalized in study period 1 before the implementation of the IV iron therapy protocol. Consequently, the patients with postoperative anemia in study period 1 without indication of ABT

were not treated with IV Monofer. Therefore, our data suggested that the patients with hemoglobin below 6.5 mmol/L but above transfusion limit might benefit from IV Monofer.

In general, few studies have reported the postoperative mortality after perioperative IV or oral iron therapy among patients undergoing major orthopedic surgical procedures [20, 23, 28, 29, 40–43]. A retrospective analysis of 2547 patients after orthopedic surgery reported a mortality of 4.8% in 1000 patients receiving either iron sucrose (Venofer) or iron sucrose + recombinant human EPO perioperatively, against 9.4% in the control population of 361 patients [23]. Likewise, Cuenca et al. found that iron sucrose preoperatively in elderly patients undergoing displaced subcapital hip fracture repair (n=20) compared to a control group (n=57) had a lower 30-day mortality rate (0 vs. 19.3%) [20]. However, as stated in the systematic review by Smith et al., the evidence for preoperative IV iron therapy in improving clinical

**Table 2** Estimation of the average treatment effect and multivariable Cox regression model among the patients with hgb postoperative day three ≤ 6.5 mmol/L stratified by treatment of postoperative anemia (30-day follow-up), n=210. The multivariable analysis is adjusted for age, gender, CCI, polypharmacy, admission source, and infection in hospital

ATE analysis	Average risk		Multivariable Cox regression model		
	Average risk	CI (95%)	Hazard ratio	CI (95%)	p value
No treatment	0.184	[0.07–0.29]	1	Reference	
ABT	0.178	[0.06–0.30]	1.00	[0.245–4.087]	0.998
IV Monofer	0.023	[0.00–0.05]	0.41	[0.089–1.887]	0.254
IV Monofer and ABT	0.095	[0.03–0.16]	1.60	[0.399–6.434]	0.505



**Table 3** Estimation of the average treatment effect and multivariable Cox regression model among patients with hgb postoperative day three  $\leq 6.5$  mmol/L stratified by no treatment and IV Monofer (30-day follow-up),  $n=132$ . The multivariable analysis is standardized for covariates

ATE analysis			Multivariable Cox regression model		
	Average risk	CI (95%)	Hazard ratio	CI (95%)	p value
No treatment	0.196	[0.027–0.364]	1	Reference	
IV Monofer	0.024	[0.000–0.051]	0.17	[0.03–0.93]	0.041*

outcomes in patients undergoing major orthopedic surgery is little. Nevertheless, our findings concur with these previous studies regarding a significant reduction in postoperative mortality although our IV iron therapy was in the postoperative phase.

Furthermore, we reported the average correction of the postoperative anemia. The increase in postoperative hemoglobin after the treatment with either ABT and/or IV Monofer was based on the first measured hemoglobin level within 14–30 days postoperatively. In summary, we found no significant difference in hemoglobin between the various treatment options. However, we acknowledge that the missing data on the patients' hemoglobin level between 14 and 30 days postoperatively was affecting the results. Thus, the patients who had hemoglobin measured between 14 and 30 days after surgery are probably not representative of the exact hemoglobin in this postoperative period of all the patients in our study. Nevertheless, when comparing our results with other studies, we acknowledge that the results on whether perioperative IV iron significantly recovers the hgb postoperatively are conflicting [24, 28, 29, 42–45]. Johansson et al. explored whether Monofer results in a better regeneration of hemoglobin-concentration and prevented anemia compared to placebo in preoperative non-anemic patients undergoing cardiac surgery. They showed that a single, perioperative 1000-mg dose of Monofer significantly increased the hemoglobin-concentration (mean 1.18 mmol/L) and prevented anemia 4 weeks after surgery [24]. Contrary, the study by Moppett et al. among older people with hip fracture showed that three doses of 200 mg Venofer on three separate days had no remarkable effect on final hemoglobin-concentration on the 7th day postoperatively [29]. Additionally, we

acknowledge that the hemoglobin recovery especially depends on when the hemoglobin is measured postoperatively as studies have shown that IV Monofer requires several weeks before the physiological effect on the hemoglobin level is measurable [24, 44]. Nevertheless, no such systematic long-term follow-up on the hemoglobin was part of the present IV iron therapy protocol in our study. Therefore, further prospective and randomized controlled trials examining the efficacy of postoperative IV Monofer therapy regarding hemoglobin recovery among older hip fracture patients are required.

#### Strength and limitations

A strength of the study is the availability of information and the registration of clinical variables from the patients' medical records and the national Shared Medication Record. Furthermore, the study shows that the implementation of the IV iron therapy protocol in the clinical setting caused a change in choice of treatment since a large percentage of the patients in study period 2 received IV Monofer. However, our study had several limitations. The observational nature of the study implies only associations therefore no causal relations can be concluded. First, the risk of confounding is related to the nature of the study. Therefore, in the survival analysis, we applied standardization to ensure that the study population had similar age, gender, comorbidity, polypharmacy, admission source, and hospital infection status to evaluate the impact of IV Monofer on outcomes. Second, we acknowledge that the size of the study population affected the statistical power. Third, we acknowledge that undergoing a hip fracture surgery is associated with an increased risk of postoperative pneumonia and pneumothorax due to intubation during the general anesthesia, time of operation, and

**Table 4** Estimation of the average treatment effect and multivariable Cox regression model among patients with hgb postoperative day three  $\leq 6.5$  mmol/L stratified by ABT and IV Monofer and ABT (30-day follow-up),  $n=78$ . The multivariable analysis is standardized for covariates

ATE analysis			Multivariable Cox regression model		
	Average risk	CI (95%)	Hazard ratio	CI (95%)	p value
ABT	0.220	[0.039–0.400]	1	Reference	
IV Monofer and ABT	0.072	[0.009–0.135]	1.34	[0.269–6.653]	0.7215

immobilization the first day postoperatively. Therefore, data regarding SpO<sub>2</sub>, arterial blood gas, and chest X-ray would have been relevant to assess whether the patients had a respiratory complication which affected the recovery and the mortality of the patients. Finally, 59% of the patients did not have available hemoglobin measurements after discharge from the hospital as patients were not systematically followed up with blood tests at their general practitioner or at the geriatrician ambulatory. Therefore, the patients who had hemoglobin measured in the 14-30-day span after surgery are likely not representative of the true hemoglobin distribution of all patients, if all patients had a hemoglobin measured in this period. In other words, the hemoglobin measured was driven by a clinical contact and thus, conclusions regarding the efficacy of Monofer in increasing the hemoglobin level postoperatively cannot adequately be made from our data.

## Conclusion

In conclusion, the patients with hemoglobin  $\leq 6.5$  mmol/L on the 3rd postoperative day who only received IV Monofer had a significantly decreased risk of 30-day mortality compared to the patients with no treatment. Furthermore, no significant differences in hemoglobin levels between 14 and 30 days post-surgery across treatment groups were found, although this was assessed in a subset of patients with available hemoglobin levels.

## Abbreviations

IV: Intravenous; EPO: Erythropoietin; ABT: Allogeneous blood transfusion; CCI: Charlson Comorbidity Index; BMI: Body mass index; ICU: Intensive care unit; ICD: International Classification of Disease; NPU: Nomenclature for Properties and Units; ATE: Average treatment effect analysis

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13018-021-02462-x>.

**Additional file 1: Table S1.** Causes of death among the patients who died within 30-days postoperatively. **Table S2.** Demographics of patients who died before hemoglobin level between day 14 to 30 was measured.

## Acknowledgements

The authors would like to thank all the participating patients and health care professionals at the Department of Orthopedic Surgery, Aalborg University Hospital, Hjørring, Denmark, and the Department of Geriatric Medicine, North Denmark Regional Hospital, Hjørring, Denmark.

## Authors' contributions

SZC: collected and analyzed data and wrote the manuscript. MLK: assisted in collecting and analyzing data and revised the manuscript. KHK: assisted in analyzing data and revised the manuscript. JR: assisted in analyzing the data. MMM, LTH, CC, and DM participated in the conception and design of the study and the protocol. The authors read and approved the final manuscript.

## Funding

There is no funding for this article.

## Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

## Declarations

### Ethics approval and consent to participate

This is a quality development project where the systematic use of IV iron was implemented in the surgical ward, and therefore, the regional ethical committee of Northern Denmark waived the need for approval. The study was registered within the Danish Data Protection Authority (reference number 2008-58-0028).

### Consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup>Center for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark. <sup>2</sup>Department of Orthopedic Surgery, Aalborg University Hospital, Hjørring, Denmark. <sup>3</sup>Unit of Clinical Biostatistics and Epidemiology, Aalborg University Hospital, Aalborg, Denmark. <sup>4</sup>Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark. <sup>5</sup>Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. <sup>6</sup>Department of Geriatric Medicine, North Denmark Regional Hospital, Hjørring, Denmark. <sup>7</sup>Department of Emergency Medicine, Aalborg University Hospital, Aalborg, Denmark.

Received: 11 March 2021 Accepted: 6 May 2021

Published online: 18 May 2021

## References

- Foss NB, Kristensen MT, Kehlet H. Anaemia impedes functional mobility after hip fracture surgery. *Age Ageing*. 2008;37(2):173–8. <https://doi.org/10.1093/ageing/afm161>.
- Gruson KI, Aharonoff GB, Egol KA, Zuckerman JD, Koval KJ. The relationship between admission hemoglobin level and outcome after hip fracture. *J Orthop Trauma*. 2002;16(1):39–44. <https://doi.org/10.1097/00005131-200201000-00009>.
- Halm EA, Wang JJ, Boockvar K, Penrod J, Silberzweig SB, Magaziner J, et al. The effect of perioperative anemia on clinical and functional outcomes in patients with hip fracture. *J Orthop Trauma*. 2004;18(6):369–74. <https://doi.org/10.1097/00005131-200407000-00007>.
- Vochteloo AJH, Borger Van Der Burg BL, Mertens BJA, Niggebrugge AHP, De Vries MR, Tuinebreijer WE, et al. Outcome in hip fracture patients related to anemia at admission and allogeneic blood transfusion: an analysis of 1262 surgically treated patients. *BMC Musculoskelet Disord*. 2011;12(1):262. Available from: <http://www.biomedcentral.com/1471-2474/12/262>.
- Dunne JR, Malone D, Tracy JK, Gannon C, Napolitano LM. Perioperative anemia: An independent risk factor for infection, mortality, and resource utilization in surgery. *J Surg Res*. 2002;102(2):237–44. <https://doi.org/10.1006/jsre.2001.6330>.
- Wu WC, Schiffner TL, Henderson WG, Eaton CB, Poses RM, Uttley G, et al. Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. *J Am Med Assoc*. 2007;297(22):2481–6. <https://doi.org/10.1001/jama.297.22.2481>.
- Van Iperen CE, Kraaijenhagen RJ, Biesma DH, Beguin Y, Marx JJM, Van De Wiel A. Iron metabolism and erythropoiesis after surgery. *Br J Surg*. 1998; 85(1):41–5. <https://doi.org/10.1046/j.1365-2168.1998.00571.x>.
- Muñoz M, Romero A, Morales M, Campos A, García-Erce JA, Ramírez G. Iron metabolism, inflammation and anemia in critically ill patients. A cross-sectional study. *Nutr Hosp*. 2005;20(2):115–20.
- Van De Wiel A. Anemia in critically ill patients. *Eur J Intern Med*. 2004;15(8):481–6. <https://doi.org/10.1016/j.ejim.2004.09.004>.
- Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: A meta-analysis. *J Trauma*. 2003;52(5):908–14.
- Shokoohi A, Stanworth S, Mistry D, Lamb S, Staves J, Murphy MF. The risks of red cell transfusion for hip fracture surgery in the elderly. *Vox Sang*. 2012; 103(3):223–30. <https://doi.org/10.1111/j.1423-0410.2012.01606.x>.
- Cuenca J, García-Erce JA, Martínez F, Pérez-Serrano L, Herrera A, Muñoz M. Perioperative intravenous iron, with or without erythropoietin, plus restrictive transfusion protocol reduce the need for allogeneic blood after

- knee replacement surgery. *Transfusion*. 2006;46(7):1112–9. <https://doi.org/10.1111/j.1537-2995.2006.00859.x>.
13. National Blood Authority Australia. Three pillars of patient blood management [Internet]. Commonwealth of Australia; 2012. p. 1. Available from: <https://www.blood.gov.au/system/files/documents/pbm-3-pillars.pdf>. [cited 2020 Aug 24]
  14. Leahy MF, Hofmann A, Towler S, Trentino KM, Burrows SA, Swain SG, et al. Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. *Transfusion*. 2017;57(6):1347–58. <https://doi.org/10.1111/trf.14006>.
  15. Meybohm P, Herrmann E, Steinbicker AU, Wittmann M, Gruenewald M, Fischer D, et al. Patient blood management is associated with a substantial reduction of red blood cell utilization and safe for patient's outcome: a prospective, multicenter cohort study with a noninferiority design. *Ann Surg*. 2016;264(2):203–11. <https://doi.org/10.1097/SLA.0000000000001747>.
  16. Muñoz M, Acheson AG, Bisbe E, Butcher A, Gómez-Ramírez S, Khalafallah AA, et al. An international consensus statement on the management of postoperative anaemia after major surgical procedures. *Anaesthesia*. 2018; 73(11):1418–31. <https://doi.org/10.1111/anae.14358>.
  17. Rineau E, Chaudet A, Chassier C, Bizot P, Lasocki S. Implementing a blood management protocol during the entire perioperative period allows a reduction in transfusion rate in major orthopedic surgery: a before-after study. *Transfusion*. 2016;56(3):673–81. <https://doi.org/10.1111/trf.13468>.
  18. Holt JB, Miller BJ, Callaghan JJ, Clark CR, Willenborg MD, Noisoux NO. Minimizing blood transfusion in total hip and knee arthroplasty through a multimodal approach. *J Arthroplast*. 2016;31(2):378–82 Available from: <https://doi.org/10.1016/j.arth.2015.08.025>.
  19. Yoon BH, Lee BS, Won H, Kim HK, Lee YK, Koo KH. Preoperative iron supplementation and restrictive transfusion strategy in hip fracture surgery. *CiO Clin Orthop Surg*. 2019;11(3):265–9. <https://doi.org/10.4055/cios.2019.11.3.265>.
  20. Cuenca J, García-Erce JA, Martínez AA, Solano VM, Molina J, Muñoz M. Role of parenteral iron in the management of anaemia in the elderly patient undergoing displaced subcapital hip fracture repair: preliminary data. *Arch Orthop Trauma Surg*. 2005;125(5):342–7. <https://doi.org/10.1007/s00402-005-0809-3>.
  21. García-Erce JA, Cuenca J, Muñoz M, Izuel M, Martínez AA, Herrera A, et al. Perioperative stimulation of erythropoiesis with intravenous iron and erythropoietin reduces transfusion requirements in patients with hip fracture. A prospective observational study. *Vox Sang*. 2005;88:235–43.
  22. Frew N, Alexander D, Hood J, Aconley A. Impact of a blood management protocol on transfusion rates and outcomes following total hip and knee arthroplasty. *Ann R Coll Surg Engl*. 2016;98(6):380–6. <https://doi.org/10.1308/rcsann.2016.0139>.
  23. Muñoz M, Gómez-Ramírez S, Cuenca J, García-Erce JA, Iglesias-Aparicio D, Haman-Alcober S, et al. Very-short-term perioperative intravenous iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients. *Transfusion*. 2014; 54(2):289–99.
  24. Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo. *Vox Sang*. 2015;109(3):257–66.
  25. Muñoz M, Naveira E, Seara J, Cordero J. Effects of postoperative intravenous iron on transfusion requirements after lower limb arthroplasty. *Br J Anaesth*. 2012;108(3):532–4. <https://doi.org/10.1093/bja/aes012>.
  26. Pujol-Nicolas A, Morrison R, Casson C, Khan S, Marriott A, Tiplady C, et al. Preoperative screening and intervention for mild anemia with low iron stores in elective hip and knee arthroplasty. *Transfusion*. 2017;57(12):3049–57. <https://doi.org/10.1111/trf.14372>.
  27. Smith A, Moon T, Pak T, Park B, Urman RD. Preoperative anemia treatment with intravenous iron in patients undergoing major orthopedic surgery: a systematic review. *Geriatr Orthop Surg Rehabil*. 2020;11:215145932093509. <https://doi.org/10.1177/2151459320935094>.
  28. Kim SK, Seo WY, Kim HJ, Yoo JJ. Postoperative intravenous ferric carboxymaltose reduces transfusion amounts after orthopedic hip surgery. *CiO Clin Orthop Surg*. 2018;10(1):20–5. <https://doi.org/10.4055/cios.2018.10.1.20>.
  29. Moppett IK, Rowlands M, Mannings AM, Marufu TC, Sahota O, Yeung J. The effect of intravenous iron on erythropoiesis in older people with hip fracture. *Age Ageing*. 2019;48(5):751–5. <https://doi.org/10.1093/ageing/afz049>.
  30. Rowlands M, Forward DP, Sahota O, Moppett IK. The effect of intravenous iron on postoperative transfusion requirements in hip fracture patients: study protocol for a randomized controlled trial. *Trials*. 2013;14(1):1 Available from: <https://doi.org/10.1186/1745-2974-14-1>.
  31. Mynster T, Krøijer R. Klinisk Retningslinje | Kræft DCCC [Internet]. [cited 2020 Aug 24]. Available from: [www.dmcg.dk/kliniske-retningslinjer](http://www.dmcg.dk/kliniske-retningslinjer)
  32. Pollock RF, Muduma G. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK. *Expert Opin Drug Deliv*. 2017;14(12):1439–46 Available from: <https://doi.org/10.1080/17425247.2017.1393412>.
  33. Mørch MM, Hansen LT. Monofer, intravenøs behandling af jernmangel - Ældre medicinsk afsnit 205B og Ortopædkirurgisk afsnit 109 [Internet]. [cited 2021 Mar 4]. Available from: <https://pri.rm.dk/Sider/30366.aspx>
  34. Pharmacosmos. Monofer 100 mg/ml solution for injection/infusion - Summary of Product Characteristics (SmPC) - (emc) [Internet]. [cited 2021 Mar 4]. Available from: <https://www.medicines.org.uk/emc/medicine/23669>
  35. Bæch J. Blodtransfusion, gældende for Region Nordjylland [Internet]. [cited 2021 Mar 4]. Available from: <https://pri.rm.dk/Sider/6658.aspx>
  36. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. *BMC Geriatr*. 2017 Oct;17(1):230. <https://doi.org/10.1186/s12877-017-0621-2>.
  37. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373–83. [https://doi.org/10.1016/0021-9681\(87\)90171-8](https://doi.org/10.1016/0021-9681(87)90171-8).
  38. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. *J Clin Epidemiol*. 1994 Nov;47(11):1245–51. [https://doi.org/10.1016/0895-4356\(94\)90129-5](https://doi.org/10.1016/0895-4356(94)90129-5).
  39. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018.
  40. Serrano-Trenas JA, Ugalde PF, Cabello LM, Chofes LC, Lázaro PS, Benítez PC. Role of perioperative intravenous iron therapy in elderly hip fracture patients: a single-center randomized controlled trial. *Transfusion*. 2011;51(1):97–104. <https://doi.org/10.1111/j.1537-2995.2010.02769.x>.
  41. Parker MJ. Iron supplementation for anemia after hip fracture surgery: a randomized trial of 300 patients. *J Bone Jt Surg - Ser A*. 2010;92(2):265–9. <https://doi.org/10.2106/JBJS.I.00883>.
  42. Heschl M, Gombotz H, Haslinger-Eisterer B, Hofmann A, Böhler N, Meier J. The efficacy of pre-operative preparation with intravenous iron and/or erythropoietin in anaemic patients undergoing orthopaedic surgery. *Eur J Anaesthesiol*. 2018;35(4):289–97. <https://doi.org/10.1097/EJA.0000000000000752>.
  43. Bernabeu-Wittel M, Romero M, Ollero-Baturone M, Aparicio R, Murcia-Zaragoza J, Rincón-Gómez M, et al. Ferric carboxymaltose with or without erythropoietin in anemic patients with hip fracture: a randomized clinical trial. *Transfusion*. 2016;56(9):2199–211. <https://doi.org/10.1111/trf.13624>.
  44. Derman R, Roman E, Modiano MR, Achebe MM, Thomsen LL, Auerbach M. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. *Am J Hematol*. 2017;92(3):286–91. <https://doi.org/10.1002/ajh.24633>.
  45. Biboulet P, Bringuier S, Smilevitch P, Loupet T, Thuile C, Pencole M, et al. Preoperative epoetin- $\alpha$  with intravenous or oral iron for major orthopedic surgery: a randomized controlled trial. *Anesthesiology*. 2018;129(4):710–20.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.